SIX Swiss Exchange · Healthcare
Invest in Galderma stock from India
Indian and foreign residents can buy Galderma (GALD) shares directly through Paasa.
By Paasa · Updated
Galderma at a glance
- Price
- CHF 163.00+CHF 0.75 (0.46%)
- Market cap
- CHF 38.01B
- Day range
- CHF 162.50 – CHF 165.30
- P/E
- 48.11
- Dividend yield
- 0.21%
- Volume
- 527.78K
- 1 month
- -4.68%
- 6 months
- +7.80%
- YTD
- +1.81%
- 1 year
- +20.38%
- 5 years
- +207.55%
Galderma statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $5.2B | $4.9B | $4.3B | $3.9B | $3.4B |
| Gross profit | $3.6B | $3.4B | $3.0B | $2.7B | $2.4B |
| Operating income | $829.0M | $710.2M | $536.0M | $353.6M | $329.0M |
| Net income | $642.2M | $254.3M | −$56.2M | −$101.7M | −$154.3M |
| Earnings per share | $2.72 | $1.07 | −$0.26 | −$0.43 | −$0.65 |
| EBITDA | $1.2B | $1.1B | $851.0M | $640.3M | $520.6M |
| Total assets | $13.4B | $12.6B | $12.3B | $12.4B | $12.5B |
| Total debt | $2.8B | $2.8B | $4.8B | $5.7B | $5.7B |
| Cash and short-term investments | $780.0M | $457.0M | $361.5M | $234.2M | $286.2M |
| Shareholders' equity | $8.2B | $7.8B | $5.3B | $4.5B | $4.5B |
| Operating cash flow | $1.2B | $488.0M | $165.0M | $114.9M | $195.7M |
| Free cash flow | $1.0B | $213.0M | $43.3M | −$49.8M | $67.7M |
| Capital expenditure | −$154.0M | −$275.0M | −$119.2M | −$164.7M | −$128.0M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in USD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Chocoladefabriken Lindt & Sprüngli | LISN.SW | CHF 89,500.00 | CHF 20.52B |
| Chocoladefabriken Lindt & Spruengli AG Partizipsch. | LISP.SW | CHF 8,580.00 | CHF 19.79B |
| Barry Callebaut | BARN.SW | CHF 1,118.00 | CHF 6.13B |
| Emmi | EMMN.SW | CHF 841.00 | CHF 4.50B |
| Bell Food | BELL.SW | CHF 237.00 | CHF 1.48B |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Galderma from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to CHF when you buy.
Step 3
Search GALD and buy
Find Galderma by name or by its ticker, GALD, and place your order.
Why invest in Galderma from India
What Galderma does
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Galderma operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Galderma stock from India?
Yes. Indian residents and NRIs can buy Galderma (GALD) shares directly through Paasa. Galderma is listed on the SIX Swiss Exchange, in the Drug Manufacturers - Specialty & Generic industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell Galderma shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the CHF/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.